Clinical trials: Diffuse Interstitial Lung Disease
Pulmonary Fibrosis, Scleroderma, Systemic
Efficacy and Safety of Oral Bosentan in Pulmonary Fibrosis Associated With Scleroderma
Clinical and experimental studies suggest that bosentan could delay the progression of interstitial lung disease (ILD) associated with systemic sclerosis (SSc), a condition for which no established efficacious treatment is…
- Trial name
- NCT00070590
- Testing
- Bosentan
- Volunteers
- 132 people
- Sponsor
- Actelion
Sarcoidosis
Prednisolone for 12 Versus 6 Months to Treat Pulmonary Sarcoidosis
In this study, the efficacy and safety of treating pulmonary sarcoidosis with 12 months vs. 6 months of prednisolone will be compared.
- Trial name
- DURASARC (NCT06654934)
- Testing
- Prednisolone
- Where
- India
- Volunteers
- 100 people
- Sponsor
- Post Graduate Institute of Medical Education and Research, Chandigarh
Scleroderma
Safety Evaluation of Dasatinib in Subjects With Scleroderma Pulmonary Fibrosis
The purpose of this study was to evaluate the safety of Dasatininb in the treatment of scleroderma pulmonary interstitial fibrosis.
- Trial name
- NCT00764309
- Testing
- dasatinib
- Where
- 13 sites in United States
- Volunteers
- 47 people
- Sponsor
- Bristol-Myers Squibb
Accelerated Phase Chronic Myelogenous Leukemia, Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome
Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral Therapy
This phase I trial studies the side effects and the best dose of sunitinib malate in treating human immunodeficiency virus (HIV)-positive patients with cancer receiving antiretroviral therapy.
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome, Acute Undifferentiated Leukemia, Adult Acute Lymphoblastic Leukemia in Remission
- Trial name
- NCT00890747
- Testing
- sunitinib malate, pharmacological study, laboratory biomarker analysis
- Where
- 11 sites in United States
- Volunteers
- 42 people
- Sponsor
- National Cancer Institute (NCI)
Pulmonary Arterial Hypertension, Diffuse Interstitial Lung Disease
Pulmonary Hypertension in Interstitial Lung Disease
HYPID study is an observational and prospective study of patients with interstitial lung disease and pre capillary hypertension diagnosed by right heart sided catheterization.
- Trial name
- HYPID (NCT01443598)
- Where
- France
- Volunteers
- 224 people
- Sponsor
- Groupe d'Etudes et de Recherche sur les Maladies Orphelines Pulmonaires
Systemic Sclerosis
MPA AUC Monitoring in Patients Receiving MMF for Diffuse Cutaneous or Pulmonary Involvement in Systemic Sclerosis
To define a target value of AUC MPA to improve the modified Rodnan score and / or respiratory impairment (DLCO or FVC) at one year in patients receiving MMF for the treatment of diffuse cutaneous or interstitial lung damage of…
- Trial name
- SCLERAMAC (NCT04244916)
- Testing
- AUC of MPA measure
- Where
- France
- Volunteers
- 2 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Idiopathic Pulmonary Fibrosis, Diffuse Parenchymal Lung Disease
Double-blind Placebo-controlled Pilot Study of Sirolimus in Idiopathic Pulmonary Fibrosis (IPF)
Idiopathic pulmonary fibrosis (IPF) is an illness characterized by progressive decline in lung function and premature death from respiratory failure.
- Conditions
- Idiopathic Pulmonary Fibrosis, Diffuse Parenchymal Lung Disease, Interstitial Lung Disease
- Trial name
- NCT01462006
- Testing
- sirolimus
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- University of Virginia
Diffuse Parenchymal Lung Disease, Frailty
Evaluation of Patients With Diffuse Parenchymal Lung Diseases Regarding Frailty
There are very few studies in the literature examining the frailty levels of diffuse parenchymal lung disease (DPLD) patients and its effect on their functional status despite the high prevalance of frailty in patients with DPLD…
- Conditions
- Diffuse Parenchymal Lung Disease, Frailty, Physical Inactivity
- Trial name
- NCT06171425
- Where
- Turkey (Türkiye)
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Hacettepe University
Interstitial Lung Disease, Scleroderma
CompRehensive Phenotypic Characterization of Patients With Scleroderma-Associated ILD and PH
Patients with interstitial lung disease (ILD) and scleroderma who develop pulmonary hypertension (PH) do not fit well into the current classification system and treatments for pulmonary hypertension.
- Conditions
- Interstitial Lung Disease, Scleroderma, Pulmonary Hypertension
- Trial name
- CRUSADE (NCT03726398)
- Testing
- Opsumit 10 Mg Tablet
- Where
- United States
- Sponsor
- Franz Rischard, DO
Mediastinal Lymphadenopathy, Mediastinal Lesions
Safety and Performance Profile of Cryobiopsy in Bronchial Endoscopy
Transbronchial cryobiopsy is a relatively recent technique, increasingly used for the diagnosis of various respiratory diseases, including neoplasms, diffuse interstitial lung diseases (ILDs), and rejection after lung…
- Conditions
- Mediastinal Lymphadenopathy, Mediastinal Lesions, Diffuse Interstitial Lung Diseases
- Trial name
- SeReCryo (NCT07301697)
- Testing
- performance of a transbronchial cryobiopsy or EBUS-cryobiopsy
- Where
- France
- Volunteers
- 30 people
- Sponsor
- University Hospital, Strasbourg, France
Pulmonary Arterial Hypertension, Diffuse Interstitial Lung Disease
HYPID (Pulmonary Hypertension in Interstitial Lung Disease) EXTENSION
HYPID-2 study is an extension of HYPID study (NCT01443598) : HYPID-2 is also an observational and prospective study of patients with interstitial lung disease and pre capillary hypertension diagnosed by right heart sided…
- Trial name
- HYPID-2 (NCT02799771)
- Where
- France
- Volunteers
- 210 people
- Sponsor
- Groupe d'Etudes et de Recherche sur les Maladies Orphelines Pulmonaires
Systemic Sclerosis
Rituximab in Systemic Sclerosis
The purpose of this study is to determine whether rituximab is effective in the treatment of articular symptoms that occur in systemic sclerosis related polyarthritis
- Trial name
- RECOVER (NCT01748084)
- Testing
- Rituximab
- Where
- France
- Volunteers
- 22 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Systemic Sclerosis, Scleroderma
Determine Effectiveness of Anifrolumab In SYstemic Sclerosis (DAISY)
The purpose of this study is to evaluate the efficacy and safety of treatment with subcutaneous anifrolumab versus placebo in adult participants with systemic sclerosis.
- Trial name
- DAISY (NCT05925803)
- Testing
- Anifrolumab (blinded), Anifrolumab (unblinded, open label)
- Where
- 150 sites in United States, Austria and 21 more
- Volunteers
- 314 people
- Sponsor
- AstraZeneca
Interstitial Lung Disease (ILD)
Safety Profile of Ultrasound-guided Transparietal Lung Biopsy in Patients With Diffuse Interstitial Lung Disease
Rationale Interstitial lung diseases (ILDs) require accurate histological diagnosis when imaging is inconclusive, yet current techniques-surgical lung biopsy and transbronchial cryobiopsy-carry significant risks and lack…
- Trial name
- TOUCANS (NCT07305220)
- Testing
- Transthoracic ultrasound-guided lung biopsy
- Where
- France
- Volunteers
- 15 people
- Sponsor
- University Hospital, Tours
Systemic Sclerosis, Scleroderma
Cyclophosphamide Systemic Sclerosis Associated Interstitial Lung Disease
By including in this study patients with significant worsening of their lung volumes and / or their DLCO (carbon monoxide diffusing capacity) in the previous year, on the basis of an open retrospective study we recently…
- Conditions
- Systemic Sclerosis, Scleroderma, Interstitial Lung Disease, Lung Fibrosis
- Trial name
- SCLEROCYC (NCT01570764)
- Testing
- Cyclophosphamide
- Where
- France
- Volunteers
- 40 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Hypersensitivity Pneumonitis
An RCT of Mycophenolate Mofetil (MMF) in Fibrotic Hypersensitivity Pneumonitis
To our knowledge, there is no randomized controlled trial assessing the efficacy of mycophenolate mofetil (MMF) in the treatment of HP.
- Trial name
- MYCOHYPE (NCT05626387)
- Testing
- Mycophenolate Mofetil plus prednisolone, Prednisolone
- Where
- 9 sites in India
- Volunteers
- 144 people
- Sponsor
- Post Graduate Institute of Medical Education and Research, Chandigarh
Systemic Lupus Erythematosus, Sjögren's Disease
A Study of BMS-986553 in Participants With Refractory Autoimmune Diseases
The purpose of this study is to evaluate the safety and tolerability of BMS-986553, CD19 in vivo Chimeric Antigen Receptor (CAR) T cells, in participants with refractory autoimmune diseases including systemic lupus erythematosus…
- Conditions
- Systemic Lupus Erythematosus, Sjögren's Disease, Rheumatoid Arthritis, Idiopathic Inflammatory Myopathies
- Trial name
- NCT07873931
- Testing
- BMS-986553
- Where
- 23 sites in United States, Belgium and 4 more
- Volunteers
- 60 people
- Sponsor
- Bristol-Myers Squibb
COPD (With - Without Rehabilitation), Diffuse Interstitial Lung Diseases
Development of a New Tool for Dyspnea Measurement in Chronic Respiratory Diseases
The purpose of this study is the psychometric validation of a self-administered dyspnea questionnaire, usable in clinical practice in order to assess dyspnea and its impact on patients with chronic respiratory diseases.
- Conditions
- COPD (With - Without Rehabilitation), Diffuse Interstitial Lung Diseases, Pulmonary Arterial Hypertension Primary or Secondary (Post Embolic .....), Cystic Fibrosis of the Adult
- Trial name
- DYSLIM (NCT02229994)
- Testing
- Cross sectional psychometric evaluation of a self-administered dyspnea questionnaire.
- Where
- France
- Volunteers
- 199 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Progressive Pulmonary Fibrosis
A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Progressive Pulmonary Fibrosis
The purpose of this study is to evaluate the efficacy, safety, and tolerability of BMS-986278 in Participants with Progressive Pulmonary Fibrosis.
- Trial name
- NCT06025578
- Testing
- BMS-986278
- Where
- 459 sites in United States, Argentina and 33 more
- Volunteers
- 1,057 people
- Sponsor
- Bristol-Myers Squibb
Diffuse Cutaneous Systemic Sclerosis, Interstitial Lung Disease
Phase 2 Safety and Efficacy Study of Tulisokibart (MK-7240/PRA023) in Subjects With Systemic Sclerosis Associated With Interstitial Lung Disease (SSc-ILD) (MK-7240-007)
The purpose of this study is to assess the safety and efficacy of tulisokibart in participants with SSc-ILD.
- Trial name
- ATHENA-SSc-ILD (NCT05270668)
- Testing
- Tulisokibart, Companion diagnostic ( CDx)
- Where
- 95 sites in United States, Argentina and 18 more
- Volunteers
- 154 people
- Sponsor
- Prometheus Biosciences, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)